{
  "id": 17857682,
  "title": "Vertex Pharma meets Q3 estimates, raises revenue guidance",
  "url": "https://urgent.news/2026/11/02/vertex-pharma-meets-q3-estimates-raises-revenue-guidance",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-02T21:31:15.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/vertex-pharma-meets-q3-estimates-raises-revenue-guidance-4992862"
  },
  "original_language": "en",
  "account": "Vertex Pharmaceuticals Inc (VRTX) delivered robust third quarter results that surpassed analyst expectations, maintaining full-year 2026 revenue guidance. Adjusted earnings per share of $4.76 met the consensus estimate, while revenue of $3.44 billion exceeded the $3.41 billion forecast. The company's broader pipeline advancements and Crinetics Pharmaceuticals acquisition contributed to its strong performance.",
  "summary": null,
  "key_points": [
    "Vertex Pharma exceeded Q3 estimates with $3.44B revenue",
    "Adjusted EPS of $4.76 met consensus expectations",
    "Guidance raised for full-year 2026 revenue"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}